# Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After Surgery

> **NCT02654119** · PHASE2 · COMPLETED · sponsor: **University of Nebraska** · enrollment: 20 (actual)

## Conditions studied

- HER2 Positive Breast Carcinoma
- Stage I Breast Cancer AJCC v7
- Stage IA Breast Cancer AJCC v7
- Stage IB Breast Cancer AJCC v7
- Stage II Breast Cancer AJCC v6 and v7
- Stage IIA Breast Cancer AJCC v6 and v7
- Stage IIB Breast Cancer AJCC v6 and v7

## Interventions

- **DRUG:** Cyclophosphamide
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Paclitaxel
- **BIOLOGICAL:** Trastuzumab

## Key facts

- **NCT ID:** NCT02654119
- **Lead sponsor:** University of Nebraska
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-11
- **Primary completion:** 2025-12-08
- **Final completion:** 2025-12-08
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2026-03-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02654119

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02654119, "Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After Surgery". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT02654119. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*